Clinical Roundup Talvey + Tecvayli show deep and durable responses in heavily pretreated MM patients with extramedullary disease June 20, 2025Vol.51 No.24
Drugs & Targets FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC June 20, 2025Vol.51 No.24
Cancer Policy Kennedy: “We’re going to end the war at FDA against alternative medicine” June 13, 2025Vol.51 No.23By Jacquelyn Cobb
Drugs & Targets FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC June 13, 2025Vol.51 No.23
Cancer Policy FDA booth stood empty at 2025 ASCO annual meeting June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Cancer Policy Makary: Level of evidence is an artificial and dogmatic construct June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Drugs & Targets FDA approves Nubeqa for metastatic castration-sensitive prostate cancer June 06, 2025Vol.51 No.22
Drugs & Targets FDA grants priority review for sevabertinib in HER2-mutant NSCLC May 30, 2025Vol.51 No.21
